These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33961526)

  • 1. Propranolol-induced hallucinations mimicking encephalopathy in a patient with liver cirrhosis.
    Al-Dury S; Molinaro A; Hedenström P
    Scand J Gastroenterol; 2021 Jul; 56(7):829-831. PubMed ID: 33961526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
    Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
    World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of rifaximin in the treatment of hepatic encephalopathy].
    Sanchez-Delgado J; Miquel M
    Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.
    Sakamaki A; Yokoyama K; Yamazaki F; Kamimura H; Kamimura K; Takamura M; Yokoyama J; Terai S
    Intern Med; 2020 Aug; 59(15):1849-1853. PubMed ID: 32321898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
    Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
    Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.
    Dunk AA; Moore J; Symon A; Dickie A; Sinclair TS; Mowat NA; Brunt PW
    Aliment Pharmacol Ther; 1988 Apr; 2(2):143-51. PubMed ID: 2979240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.
    Courson A; Jones GM; Twilla JD
    J Pharm Pract; 2016 Jun; 29(3):212-7. PubMed ID: 25586470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.
    Tapper EB; Finkelstein D; Mittleman MA; Piatkowski G; Chang M; Lai M
    Clin Gastroenterol Hepatol; 2016 May; 14(5):753-9. PubMed ID: 26407750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pay more attention to hepatic encephalopathy].
    Labenz J
    MMW Fortschr Med; 2014 Feb; 156(2):60-1. PubMed ID: 24934059
    [No Abstract]   [Full Text] [Related]  

  • 18. Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin.
    Sousa AL; Salgado P; Alves JE; Silva S; Ferreira S; Magalhães M
    Tremor Other Hyperkinet Mov (N Y); 2019; 9():. PubMed ID: 31413898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy.
    Fujiwara Y; Suzuki K; Yusa K; Eizuka M; Miura M; Watanabe Y; Takahashi H; Takikawa Y
    Intern Med; 2021; 60(7):1027-1033. PubMed ID: 33790139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic encephalopathy: pathophysiology and emerging therapies.
    Sundaram V; Shaikh OS
    Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.